Hyperimmune Globulin for Pneumococcal Infection Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Standard intravenous immunoglobulin (IVIG) preparations do not consistently provide adequate opsonic antibody levels against Streptococcus pneumonia, leading to persistent upper respiratory tract infections in immunocompromised patients despite adequate total immunoglobulin and anti-pneumococcal antibody levels, resulting in increased antibiotic use and medical expenditures.
Innovation Solution
Development of a hyperimmune globulin composition with elevated titers of opsonic anti-pneumococcal antibodies, produced by vaccinating plasma donors with pneumococcal vaccines and pooling their plasma to create a preparation that is intravenously injectable, providing broad reactive opsonic antibodies against multiple S. pneumonia serotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If standard IVIG preparations are used, then total immunoglobulin levels are adequate, but opsonic antibody levels against S. pneumonia remain insufficient
Solution Approach 1:
The patent applies local quality by creating a hyperimmune globulin preparation with locally enhanced opsonic antibody properties against S. pneumonia, while maintaining overall immunoglobulin structure. The preparation is enriched specifically with opsonic antibodies through donor selection and plasma fractionation, providing targeted protection without requiring changes to the entire immunoglobulin molecule structure.
Solution Approach 2:
The patent changes the concentration parameter of opsonic antibodies by selecting plasma donors with high titers of anti-pneumococcal antibodies and concentrating these antibodies through fractionation processes. This results in a preparation with significantly elevated opsonic antibody levels (minimum 1:8 dilution titer) compared to standard IVIG, while maintaining other immunoglobulin parameters within acceptable ranges.
2Quantity of substance
If standard IVIG is administered, then total antibody levels are sufficient, but protection against upper respiratory tract infections is inadequate
Solution Approach 1:
The patent enhances local quality by specifically enriching the immunoglobulin preparation with opsonic antibodies that target S. pneumonia, the primary causative agent of upper respiratory tract infections. This targeted approach provides localized protection against respiratory infections while maintaining overall immunoglobulin function, addressing the specific vulnerability to pneumococcal infections.
Solution Approach 2:
The patent applies preliminary action by pre-selecting plasma donors who have been vaccinated against S. pneumonia and have developed high titers of opsonic antibodies. This preliminary immunization of donors ensures that the resulting hyperimmune globulin preparation contains pre-formed protective antibodies, providing immediate passive immunity upon administration to immunocompromised patients.
3Reliability
If plasma donors are vaccinated to produce hyperimmune globulin, then opsonic antibody titers are elevated, but production complexity increases
Solution Approach 1:
The patent simplifies the production process by performing preliminary vaccination of plasma donors before plasma collection. This preliminary immunization ensures that donors already have high titers of opsonic antibodies, eliminating the need for complex post-collection antibody concentration or purification steps. The high-titer plasma is obtained directly from vaccinated donors, reducing manufacturing complexity.
Solution Approach 2:
The patent applies self-service by allowing the vaccinated donors' own immune systems to produce the high-titer opsonic antibodies needed for the preparation. The donors' bodies naturally generate the required antibodies through vaccination, eliminating the need for external antibody synthesis or complex biotechnological production methods. This biological self-service approach simplifies the overall production process.
Data Source
AI summary
The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.